As of Jul 02
| +0.06 / +2.84%|
The 3 analysts offering 12-month price forecasts for Transition Therapeutics Inc have a median target of 4.66, with a high estimate of 10.00 and a low estimate of 2.62. The median estimate represents a +114.83% increase from the last price of 2.17.
The current consensus among 4 polled investment analysts is to Buy stock in Transition Therapeutics Inc. This rating has held steady since June, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.